drugset / Trial / NCT01043120

Effect of Oxytocin Antagonist on Reduction of Uterine Contractions

NCT01043120

Phase 2 Completed 99 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of this clinical research trial was to evaluate the effects of barusiban compared to placebo on uterine contractions on luteal phase uterine contractions in oocyte donors supplemented with progesterone.

Timeline

Start
2010-02
Primary completion
2010-05
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Barusiban Unknown 19 mg Intravenous

Indications

No indication recorded.